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Abstract
In the context of solid organ transplantation, screening of recipients and organ donors is crucial, and should be performed with great
rigour to minimize the reactivation or the risk of transmission of certain infectious processes. This review aims to update understanding
of the possible pathologies involved, as well as of emerging infections that, as a result of globalization, are gaining increasing prominence
on a daily basis.
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Hot topics
 Each combination of donor and recipient should be assessed
individually.
 Active infections in donors do not necessarily preclude
organ donation. Donors with certain infections may be
suitable for donation on the basis of close monitoring and
preemptive or prophylactic measures.
 Nucleic acid testing (NAT) should routinely be used to test
human immunodeﬁciency virus (HIV) and hepatitis C virus
(HCV) infection in high-risk donors.
 Origin and travel history of both donor and recipient is of
paramount importance in order to screen for geographically
restricted infections.
Introduction
Infectious complications continue to be the primary cause of
morbidity and mortality after organ transplantation. Many of
these complications have an exogenous origin, including those
caused by pathogens transmitted by the transplanted organ.
Sometimes, it is the recipient who previously has a chronic or
latent infection that can reactivate after the procedure. Rigorous
screening of the recipient and the donor for latent and active
infections is essential for optimizing outcomes after transplan-
tation and serves to prevent the inadvertent use of unsuitable
organs and prompt targeted anti-infective prophylaxis or
preemptive therapy or infection surveillance measures
post-transplantation. The evidence for recommending inter-
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ventions in this ﬁeld is based on case reports and series and
cohort studies. In addition to national guidelines, local epidemi-
ology should always be considered before taking any decision
regarding the risk of transmission of an infectious disease.
For this chapter the authors propose the Alliance-O [1]
classiﬁcation of risk levels regarding disease transmission, in
addition to the Infectious Diseases Society of America grading
system for ranking recommendations [2], as follows:
1. Unacceptable risk (RL1): absolute contraindication, with the
exception of some life-saving transplantation procedures in
the absence of other therapeutic options on a case-by-case
basis.
2. Increased but acceptable risk (RL2): includes cases where
transmissible microorganisms or diseases are identiﬁed
during the evaluation process of the donor, but organ
utilization is justiﬁed by the speciﬁc health situation of the
recipient or the severity of their clinical condition.
3. Calculated risk (RL3): includes all cases where, even in the
presence of transmissible diseases, transplantation is
allowed for recipients with the same disease or with a
protective serological status, in cases with broad-spectrum
antibiotic therapy of a minimum duration (24 h) and those
with documented bacteraemia who have started targeted
antibiotic therapy.
4. Not assessable risk (RL4): includes cases where the
evaluation process does not allow an appropriate risk
assessment for transmissible diseases.
5. Standard risk (RL5): includes cases where the evaluation
process did not identify a transmissible disease.
Screening of Potential Recipient and Donor
for Latent Infection
All infection screening begins with thorough medical and social
histories and physical examination. In this section we include
serological and microbiological testing of donors and recipients
as summarized in Table 1.
Human immunodeﬁciency virus
Donor. The transmission of HIV by organ transplantation is well
documented (RL1).Many countries have policies and regulations
that prohibit organ donation from HIV-infected persons,
although recently, utilization of HIV-infected organs for
HIV-infected kidney recipients has been carried out in South
Africa [3]. An enzyme-linked immunoassay (EIA) for both
antibodies and antigen for HIV-1/2 is the preferred initial test,
and repeatedly reactive results are conﬁrmed by Western
immunoblot assay. In case of a high-risk donor (a drug addiction
during the past 2 years, either intravenous or intranasal,
frequently changing sexual partners during the past 6 months,
sexual partners of people with viral infections such as hepatitis B
virus (HBV), HCV, HIV or human T lymphotrophic virus
(HTLV)-I/II, or imprisoned during the past 3 months), extended
screening by NAT is highly recommended.
Recipient. Although recipients must also be screened for HIV,
due to the efﬁcacy of current antiretroviral therapy, HIV
infection is no longer a contraindication for transplantation.
Currently, organ transplantation is performed in patients with
HIV infection with no detectable viral replication, a CD4+
lymphocyte count above 200/lL and therapeutic reserve.
Recommendations.
 Both donor and recipient should be tested for HIV infection
by EIA. Grade: AII.
TABLE 1. Recommended infection screening of potential
donor and recipient
Test or study Donation if test positive
Medical evaluation and studies
Medical and social history*
Physical examination*
Chest radiograph*
Bronchoscopy with
bronchoalveolar lavage**
Not contraindicated. Individual
evaluation in the case of multidrug
resistance, and fungal and
mycobacterial colonization.
Treat the recipient.
Tests for bacterial infection
Rapid plasma reagin (RPR) or
other serological test
for syphilis*
Not contraindicated but treat
the recipient
Tuberculin skin test***
Blood cultures† Not contraindicated but treat the
recipient. Individual decision in
the case of MDR bacteria.
Tests for viral infection
HIV 1/2 antibody* Contraindicated but considered
for HIV-positive recipient
Cytomegalovirus IgG antibody* Not contraindicated but essential
to deﬁne prophylactic strategy
after procedure depending on
recipient serology
EBV IgG antibody* Not contraindicated but essential to
monitor EBV-negative recipients,
especially children
HBsAg* Contraindicated but considered for
HBsAg+ recipients or HBV protective
immunity
HBcAc/‘HBc alone’* Not contraindicated but consider
antiviral prophylaxis for liver and
HBV non-immune recipients
HCV antibody* Contraindicated but considered for
HCV+ recipients
Tests for parasitic infection
Toxoplasma IgG antibody‡ Not contraindicated but consider
prophylaxis for heart transplant
*, test recommended for both donor and recipient;
**, test recommended for lung donor and recipient;
***, test recommended for recipient;
†, test recommended for donor;
‡, test recommended for heart donor and recipients, especially in areas of high
endemicity.
HIV: human immunodeﬁciency virus; EBV: Epstein-Barr virus; HBsAg: hepatitis B
virus antigen; HBV: hepatitis B virus; HBcAc: hepatitis B total core antibody; HCV:
hepatitis C virus
Extended information in the text.
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 The high-risk donor should be screened for HIV infection by
NAT. Grade: AIII.
Hepatitis viruses
Donor. Hepatitis A (HAV) and E virus (HEV) infections are not
a risk for transplantation (RL5) except in cases of acute
infection in the donor.
Organ donors are screened for serological evidence of HBV
infection with immunoassays for surface antigen (HBsAg) and
total core antibody (HBcAb). HBsAg+ organs may be consid-
ered for use in recipients who are HBsAg+ or who show
protective immunity to hepatitis as a result of immunization
(HBsAb titer ≥10 IU/mL) or natural infection [4]. HBsAg+
organs are rarely accepted for recipients with no prior
exposure or immunity to HBV except in geographical locations
with HBV hyperendemicity or life-threatening situations.
Post-transplantation, hepatitis B immune globulin plus an
antiviral agent are administered to recipients of HBsAg +
organs, regardless of immune status, although prophylaxis does
not prevent transmission of infection in all cases (RL2). All
recipients require laboratory monitoring after transplantation
for acquired HBV. The hepatitis B serological proﬁle called
‘HBc alone’ (e.g. HBsAg, HBcAb+, HBsAb) deserves special
consideration. This may be seen with early hepatitis B infection
or later (resolved) infection. Alternatively, it can represent a
false-positive result, especially if risk factors for hepatitis B are
absent. Results demonstrating HBcAb+, HBsAb+ are consis-
tent with resolved infection although hepatitis B virus may
persist in the liver. The risk of transmission of infection from
an HBsAg, HBcAb+, HBsAb+/ donor to a susceptible
non-hepatic organ recipient is low (RL2-3). Thus, donors with
isolated HBcAb+ are increasingly utilized in non-liver organ
transplantation and recipients with protective immunity
require no therapy post-transplantation. However, HBV
non-immune recipients and liver recipients should undergo
serial laboratory testing for HBV infection or alternatively
receive antiviral prophylaxis with an agent such as lamivudine.
All cases with potential HBV transmission should be discussed
with an expert in the ﬁeld.
For HCV, viral transmission from an infected donor to a
seronegative recipient is substantial [5] (RL1). Donors are
screened with a third-generation EIA, which reduces consid-
erably the so-called ‘window effect’, with a sensitivity of at
least 95%. HCV+ organs are generally excluded from
transplantation, with the exception of emergency situations
if allowed by law, often with preferential allocation to
HCV-infected recipients. This strategy has proved to be safe
and effective in the setting of kidney transplantation [6]. In
high-risk donors, NAT is highly recommended.
Recipient. HAV can cause severe hepatitis, especially in older
patients and in the setting of liver transplantation. As it is
possible to effectively vaccinate the recipient before transplan-
tation, detection of IgG antibodies by EIA is recommended.
HEV may reactivate and lead to cirrhosis in the transplant
recipient but current data are inconclusive so recommenda-
tions cannot be set.
HBV screening in the recipient is recommended to be
carried out sequentially. The key marker is HBsAg. If negative,
the recipient should be vaccinated, unless already immunized,
which is determined by quantitative determination of anti-HBs
antibodies (a value greater than 10 IU/mL suggests immunity).
If the candidate is positive for HBsAg, a full serological proﬁle
for HBV should be performed as well as viral DNA quanti-
ﬁcation. All these markers are particularly relevant for
establishing either treatment or prophylaxis patterns before
and after transplantation.
Recipients with acquired HCV are at risk for chronic
infection and progressive liver disease, the course of which
may be accelerated by immunosuppressive therapy. The
screening method for HCV in the recipient consists of an
EIA. In patients receiving haemodialysis, the screening of
antibodies is less sensitive than in the general population, so
NAT may be a valid alternative to resolve doubtful cases. It is
advisable to determine the viral load and the HCV genotype,
both relevant to patient management before and after
transplantation.
Recommendations.
 Both donor and recipient should be screened for HBV and
HCV infection by serology. Grade: AII.
 High-risk donors should be screened for HCV infection by
NAT. Grade: AIII.
Herpesviruses
Cytomegalovirus. Cytomegalovirus (CMV) infection is commonly
acquired through organ transplantation (RL3). CMV donor
positive/recipient negative (D+/R-) serostatus is the greatest
risk factor for CMV infection post-transplantation, although
CMV seropositive recipients may develop disease reactivation
(CMV D+ or D-/R+) or donor-related infection (CMV D+/R+).
Therefore, organ donors and recipients should be tested for
prior (latent) CMV infection by EIA to establish risk assessment
and deﬁnition of an appropriate surveillance and/or antiviral
prophylaxis to be instituted after transplantation.
Epstein-Barr virus. Epstein-Barr virus (EBV) infection is associ-
ated with the development of post-transplant lymphoprolifer-
ative disorders (PTLDs). EBV transmission to a seronegative
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recipient is the greatest risk factor for PTLD (RL3). Hence,
EBV D+/R-, particularly in children, requires regular follow-up
and consideration for speciﬁc monitoring strategies and
therapies if viraemia is identiﬁed. EBV serology should be
performed in all donors and recipients.
Other herpesviruses. Strategies for prevention have not been
deﬁned for other herpesviruses such as human herpes virus-6,
-7 or -8, for which a high proportion of adults are seropositive.
Thus, no recommendations can be made at this time.
Recommendations.
 Both donor and recipient should be screened for CMV
infection by serology. Grade: AII
 Both donor and recipient should be screened for EBV
infection by serology, especially if the recipient is a child.
Grade: AII.
Treponema pallidum
Donor. Transmission of T. pallidum by organ transplantation
has been documented [7]. Syphilis is not a contraindication to
organ donation (RL3). Donors are screened for serological
evidence of syphilis with a non-treponemal assay such as the
rapid plasma reagin test, which should be conﬁrmed later with
a treponemal immunoassay. Syphilis is never a contraindication
for using organs; penicillin should be administered to recipients
of serologically reactive donors.
Recipient. The recipient should also be screened to rule out
latent syphilis in order to be treated before transplantation.
Recommendations.
 Both donor and recipient should be screened for syphilis by
serology. Grade: AII.
Mycobacterium tuberculosis
Donor. Donor-derived tuberculosis (TB) has been occasionally
reported. The evaluation of the deceased donor for TB relies on
the medical history, endemic exposures and radiographic
ﬁndings as time does not allow for a tuberculin test and
information provided by interferon-gamma release assay (IGRA)
will be expected after procurement. Organs from donors with
known active TB infection should be discarded (RL1), and lungs
with residual tuberculous lesions should not be used for
transplantation. A history of latent TB without evidence of
active infection is not a contraindication to donation (RL3) but
administration of preventive therapy to all recipients should be
considered, especially for lung recipients [8].
Recipient. Infections with M. tuberculosis have serious implica-
tions for the transplant recipient, with reported mortality rates
up to 30%. Most cases are attributed to reactivation of latent
infection in the recipient. A history of clinical or radiological
TB and the treatment received should be assessed in all
recipients and a tuberculin test or a TB interferon-gamma
release assay (IGRA) test should be carried out in order to
decide chemoprophylaxis. Active disease in the recipient is a
contraindication for transplantation, although it has been
suggested that once adequate treatment is established and
smears are negative, the transplantation could be performed
[9].
Recommendations.
 A tuberculin test or TB IGRA test should be performed in
the recipient with no previous history of TB. Grade: AII.
 A TB IGRA test may play a role in screening for latent TB in
a donor with no previous history of TB. Grade: CIII.
Toxoplasma gondii
Transmission of an infection with T. gondii occurs most
commonly when a seronegative recipient receives an organ
from a seropositive donor (RL3). Whereas the occurrence of
toxoplasmosis following non-cardiac organ transplantation is
low, the reported prevalence in serologically mismatched (D+/
R) heart and heart-lung recipients in the absence of
antimicrobial prophylaxis can be as high as 75% due to the
transmission of T. gondii cysts present within cardiac tissue.
Less commonly, seropositive recipients may manifest reacti-
vation of latent infection.
Recommendation. Both donor and recipients (especially for
cardiac procedures) should be screened for serological
evidence of infection. Grade: AII.
Considerations for the Donor and the
Recipient with Acute Infection
Donor
Bacterial and fungal colonization or infection is frequently
identiﬁed in potential organ donors as a consequence of
intensive care and invasive resuscitative efforts. These patho-
gens can be transmitted to the recipient and could result in
potentially fatal early post-transplant complications, such as
bacteraemia, myocarditis or mycotic aneurysm (RL2-3 accord-
ing to pathogen, susceptibility testing and degree of control of
the active infection). Staphylococcus aureus, Pseudomonas aeru-
ginosa and Candida spp., in particular, are more prone to cause
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these serious complications. Infections without systemic
spread are not a contraindication for transplantation (RL5),
with the exception of the infected organ (RL1-3). Bacteraemia
and focal infections, including bacterial meningitis and endo-
carditis, are not absolute contraindications to organ donation
(RL2-3) if the cause is identiﬁed and appropriate antimicrobial
therapy is administered to donors for 48 h or more and
infection is clinically controlled [10]. Nevertheless, donors
who die due to meningoencephalitis caused by Cryptococcus
neoformans or Mycobacterium tuberculosis should not be used
(RL1). To identify subclinical infections, blood cultures should
be collected at the time of organ procurement, especially if the
donor has been hospitalized for more than 48–72 h. Generally,
recipients who receive organs from bacteraemic or fungaemic
donors should receive targeted antimicrobial therapy for a
period of 7–14 days [11].
The lung is the most common site of infection in donors.
When lung transplantation is under consideration, gram stain
and culture of respiratory secretions should be performed.
Utilization of lungs with gram-negative bacteria or fungal
infections is controversial (RL2-3); some experts favour
discarding these organs, while others advocate their use with
aggressive antibiotic therapy. Supporting the latter argument, a
recent retrospective study demonstrated a high rate of
transmission of respiratory tract pathogens to lung recipients
(>40%) but overall patient survival was not different to that of
recipients of uninfected lungs [12]. Lung recipients should
receive treatment according to susceptibility patterns of
recovered microorganisms. Additionally, potential donors
with upper or lower respiratory tract infection symptoms
should be microbiologically tested to rule out inﬂuenza
infection during the annual inﬂuenza epidemic. Donors with
conﬁrmed or suspected inﬂuenza infection, having received
antiviral treatment or not, can be considered for SOT
provided that the recipient is prophylactically treated with
neuraminidase inhibitors. These donors should be ruled out in
the case of lung or intestine transplantation [13].
Patients who die due to meningoencephalitic or myelitic
symptoms or any disease mimicking a viral infection of
undetermined aetiology should be rejected as potential organ
donors as transmission of undetected active viral infection
such as rabies, lymphocitic choriomeningitis virus or arenav-
iruses has been well documented [14] (RL1). All diseases
secondary to prions are an absolute contraindication for
transplantation (RL1).
Recipient
As a general principle, an active infection (bacterial, fungal, viral
or parasitic) from the recipient must be ruled out before the
start of immunosuppression. There are few data about the
minimal time interval between infection and transplantation. It
has been recommended to be a minimum of 2 weeks after the
recovery of an active infection but can be shortened in the case
of life-threatening situations. However, as in cases of cholangitis
in liver transplantation, infections of ventricular assistance
devices in heart transplantation or pulmonary colonization with
Pseudomonas aeruginosa in patients with cystic ﬁbrosis in lung
transplantation, infection will only be resolved with the proce-
dure and, therefore, transplantation should not be delayed.
Active infections due to fungi and other opportunistic organisms
may constitute a contraindication for transplantation (RL1).
Recommendations.
 The donor with an active bacterial infection should receive
antibiotic therapy before organ procurement (preferably for
more than 48 h). Grade: AII. Treatment should be continued
in the recipient. Grade: AII.
 Blood cultures from the donor should be collected at the
time of organ donation. Grade: AII.
 A bronchial washing should be performed in both donor and
recipient of lung transplantation at the moment of proce-
dure. Grade: AII.
Other Measures to Minimize Infection in the
Recipient
Donor
Some transplant centres take smears during organ recovery
from the abdomen or thoracic cavity and before implantation
from the organ preservation ﬂuid as transmission has been
well documented (RL2-3). The general use of this procedure
for organ preservation ﬂuid is highly controversial, as therapy
for a contaminated ﬂuid is not considered mandatory and
should be administered on a case-by-case basis [10,15].
Recipient and donor
Infection and colonization of the recipient by multidrug-resis-
tant (MDR) bacteria has been the cause of serious complica-
tions in some transplant units. Colonization does not imply
infection, but knowledge of colonization can help guide
antibiotic prophylaxis during the procedure or empirical
antibiotic coverage in the face of an infectious complication
after transplantation. The presence of carbapemenase-pro-
ducing Gram-negative bacteria, panresistant P. aeruginosa and
vancomycin-resistant Enterococcus (not as prevalent in Europe
as in the USA) and, in general, any MDR microorganism in both
donor and recipient constitutes a very high-risk situation and a
careful risk-beneﬁt analysis should be performed.
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Recipient
The pre-transplant period, while the patient is not immuno-
suppressed, represents a great and ‘last’ opportunity to
complete vaccination. Ideally, all candidates should be fully
vaccinated before transplantation because the response to
vaccination is weak after the procedure. The vaccines to be
administered in the transplant candidate are summarized in
Table 2. Prior to vaccination, it is recommended to determine
the immune status for those pathogens, whose vaccines confer
immunity for a long period of time (varicella, measles, mumps,
rubella, polio, pertussis and diphtheria). There is no consensus
to establish the ideal time to vaccinate after transplantation but
at least 3–6 months after transplantation or a rejection
therapy is advisable to avoid ‘over-immunosuppressive’ peri-
ods. As vaccinations by live vaccines may result in transmission
of a vaccine-derived pathogen to the recipient (RL1-2), it is
also imperative to determine if the donor received vaccination
during the past 4 weeks against inﬂuenza (inhaled live vaccine),
varicella, rotavirus, measles, mumps, rubella, BCG, smallpox,
cholera (oral vaccine), yellow fever, Salmonella typhi (oral
vaccine) or polio (oral vaccine).
Recommendations
 Identiﬁcation of MDR bacteria colonization in the recipient
is useful for deﬁning antibiotic prophylaxis in some instances
(antibiotic pressure, previous and frequent admissions to
hospital). Grade: BIII.
 The recipient should be screened for potential preventable
diseases and vaccination should be administered accordingly
thereafter. Grade: AII.
Considerations for Special Situations: the
Living Donor, the Traveller and the
Immigrant
Evaluation for infection must be performed in a short time,
usuallywithin hours, in the deceased donor. In this little periodof
time the laboratory must generate sufﬁcient information to
determine the suitability of the potential donor. However, there
is the possibility that certain infections are at an early stage or in
the window period prior to the generation of antibodies. This is
the main difference with the living donor, in whomwe have time
enough to act in the case of detecting an infection, which can be
treated and transplantation deferred until resolution. In the case
of living donors, donor serology for HBV, HCV and HIV should
be repeated 7–10 days before transplantation to detect new
infections and reduce the window period.
The epidemiology of infectious diseases should be taken
into account in any decision related to the risk assessment of
disease transmission. Indeed, the risk of transmission of rare
infections is increasing with greater global mobility. In
Tables 3, 4,and 5, and we summarize the main information
about screening and recommendations for geographically
restricted infections [16].
Considerations about the Best Test to
Perform the Screening
False-negative results occur in different scenarios: haemodilu-
tion, ‘window period’, incorrect sampling or inappropriate test
quality. False-negative test results can occur, for example, with
HIV and HCV antibody testing. As a consequence, transmis-
sion events involving HIV and HCV seronegative donors have
occurred. For this reason, donors in whom the potential for
recent infection is suspected are generally considered only for
recipients in life-threatening situations, and additional consent
must be obtained from the recipient before transplant. Thus,
the use of viral NAT to supplement serological testing of
high-risk donors should be performed [18]. With NAT, the
window period from infection to viral detection can be
reduced to 5–10 days for HIV (from 22 days), 3–5 days for
HCV (from 66 days), and to a lesser extent, 20–22 days (from
44 days) for HBV. However, NAT is expensive and not
available in many institutions worldwide, requires additional
testing time and false-positive tests may result in loss of organs.
TABLE 2. Recommended vaccines for recipients
Vaccine Scheme Before Tx After Tx Booster
Varicella 2 doses (0, 1 month) Last dose 1 month before Tx Contraindicated if active immunosuppression –
MMR 2 doses (0, 1 month) Last dose 1 month before Tx Contraindicated if active immunosuppression –
S. pneumoniae 1 dose Last dose 2 weeks before Tx After 6 months of Tx Once after 5 years
Inﬂuenza 1 dose Last dose 2 weeks before Tx After 6 months of Tx Every year
HBV Fast (0, 1, 2, 6-12 months)
Accelerated (0, 7, 21 days, 12 months)
Double dose if high immunosuppression
Last dose 2 weeks before Tx After 6 months of Tx If anti-HBs
<10 UI/l (double dose
revaccination)
HAV 2 doses (0, 6 months) Once in non-responders
(anti-HAV <10 UI/l)
dT According to previous immunization status Every 10 years (dT or dTpa)
Tx, transplantation; MMR, measles, mumps, rubella; HBV, hepatitis B virus; HAV, hepatitis A virus; dT, diphtheria and tetanus; dTpa, diphtheria, tetanus and pertussis.
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TABLE 4. Geographical distribution of infectious agents
Infectious agent Geographical distribution
HTLV-1/2 Relatively high HTLV-1 seroprevalence in southwestern Japan (up to 10%), in several
countries in the Caribbean area including Jamaica and Trinidad (up to 6%), in Latin
America (Bolivia, Peru), in several sub-Saharan Africa countries (up to 5%), and in
localized areas of Iran and Melanesia (less than 5%). In areas where the disease is not
endemic, such as Europe and North America, HTLV-1 infection is found mainly in
immigrants, their offspring and sexual contacts.
HTLV-2 has been described mainly in IVDU populations of the United States, Europe,
South America (Brazil) and southeast Asia (Vietnam) and their sexual contacts, as well
as in populations of native Amerindians
WNV Africa, Asia, the Middle East, Europe, North America, the Caribbean Islands and Latin America.
The incidence of WNV disease is seasonal in the temperate zones of North America,
Europe and the Mediterranean Basin, with peak activity from July through to October
Rabies virus Rabies virus-free countries and territories are islands of the developed world (e.g. Japan and
New Zealand) and the developing world (e.g. Barbados, Fiji and Seychelles), and parts of northern
and southern continental Europe (e.g. Greece, Portugal and the Scandinavian countries)
Coccidioides immitis (coccidioidomycosis) Southwestern United States and northern Mexico, where they are endemic. Also found in parts
of Argentina, Brazil, Colombia, Guatemala, Honduras, Nicaragua, Paraguay and Venezuela.
Hyperendemic areas include Kern, Tulare and Fresno counties in the San Joaquin Valley of
California and Pima, Pinal and Maricopa counties in Arizona
Histoplasma capsulatum (histoplasmosis) Mississippi and Ohio River valleys, central America, and certain areas of southeast Asia and
the Mediterranean basin
Paracoccidioides brasiliensis (paracoccidiomycosis) Latin America, from Mexico (23°N) to Argentina (34°S); not present in all countries within this
area (Chile and some of the Caribbean Islands are not affected)
Blastomyces dermatitidis (blastomycosis) South central and north central United States, extending into Wisconsin, Minnesota and the
southern portions of Ontario, Manitoba, Saskatchewan and Alberta. Also found in the
Mediterranean basin and parts of Africa
Plasmodium spp. (malaria) P. falciparum is found in sub-Saharan Africa, southeast Asia and the Indian subcontinent as well as
in South America, Haiti, the Dominican Republic, Jamaica and areas of Oceania.
P. malariae and P. ovale are more prevalent in sub-Saharan Africa.
P. vivax is prevalent in areas of southeast Asia, the Indian Subcontinent and central and
South America.
P. knowlesi is found in Southeast Asia
Trypanosoma cruzi (Chagas’ disease) From the south of the United States to Argentina and Chile (excluding the Caribbean area).
Strongyloides spp. (strongyloidiasis) Non-uniform distribution throughout the world, including Europe, in the tropics and other areas with
warm and humid climates, mainly in southeast Asia, sub-Saharan Africa, Brazil (where prevalence
rates are close to 60%), and the southern United States
Taenia solium (cysticercosis) Worldwide distribution, predominating in areas where there is porcine livestock and, because of this,
it is rare in Islamic countries. Greater incidence in developing countries and endemic in parts of Asia,
Africa and Latin America
Echinococcus spp. E. granulosus (cystic hydatidosis) is found in the coastal areas of the Mediterranean, South America,
southern areas of Russia, central Asia, China, Australia and some areas of Africa.
E. multilocularis (alveolar hydatidosis) is present in the northern hemisphere, mainly in central Europe,
Russia, central Asia, North America (especially in hunters in Canada and Alaska) and west China.
E. voegeli is prevalent in central and South America (Colombia, Venezuela, Brazil and Panama).
Filariae (ﬁlariasis) North Africa, Caribbean, South America (in certain countries), Yemen, Indian subcontinent, southeast
Asia and Paciﬁc area of Oceania
Schistosoma spp. S. haematobium, S. intercalatum and S. mansoni are endemic in sub-Saharan Africa, and the latter is also
found in Brazil, Venezuela and certain areas of the Caribbean
S. japonicum occurs mainly in China, Indonesia and the Philippines
S. mekongi is present in Cambodia and Laos
Clonorchis spp. China, Taiwan, Korea and Japan
Opistorchis spp. Eastern Europe, countries of the former Soviet Union, India and Thailand
Paragonimus spp. Japan, India, certain islands of the Paciﬁc, west and central Africa, and South and central America
Fasciola spp. Europe, East Asia, South Africa, North and South America, the Caribbean and Australia
Babesia spp. (babesiosis) Temperate zones of the United States and Europe, even though isolated cases have also been
described in China, Taiwan, Egypt, South Africa, Mexico and, more recently, India
Entamoeba histolytica (amebiasis) Central and South America, Africa and the Indian subcontinent.
Trypanosoma brucei (sleeping sickness) Trypanosoma brucei gambiense is found in west and central Africa
Trypanosoma brucei rhodesiense is present in east Africa
TABLE 5. Summary of recommended screening for geographically restricted infections in both donor and recipient depending
on origin.
Test
Region
Central and South America North Africa
Sub-Saharan
Africa
Indian
subcontinent
Southeast
Asia
HTLV serology Always Always Always Always Always
NAT for Plasmodium spp Central America
and Amazones
No Always Always Always
Stool examination Always Always Always Always Always
Urine examination No Egypt Always No No
Strongyloides stercolaris serology Always Always Always Always Always
Schistosoma spp serology Caribbean, Venezuela
and Brazil
Always Always No Always
Trypanosoma cruzi serology Always (not Caribbean) No No No No
Paracoccidioides brasiliensis serology Brazil No No No No
Histoplasma capsulatum and
Coccidioides immitis serology
Always No Western Africa
(histoplasmosis)
No No
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So, at the present time, NAT is not consistently employed,
except in special situations as described above [19].
Considerations for the Right Decision and to
Diminish the Risk of Transmission
First of all, the risk of transmission of an infection in SOT
cannot be reduced to zero. However, the most important risk
factor for the patient is to die whilst on the transplant waiting
list due to not getting an organ in time. So, the shortage of
suitable organ donors is currently one of the most important
barriers in organ transplantation. The disparity between
demand and supply has led the transplant community to look
beyond relatively young, stable deceased organ donors toward
more marginal candidates who may potentially transmit
diseases to their recipients. The use of medical devices,
treatment of patients in hospital areas that have signiﬁcant
rates of bacterial contamination and, most importantly, the
presence of certain medical conditions or ‘risk behaviours’ in
the potential organ donor are important factors that facilitate
bacterial or viral infection. Hence, it is of paramount impor-
tance to implement control mechanisms to ensure rapid
recognition of positive cultures from organ procurement
procedures and transplantation and its prompt communication
to treating physicians. However, in the end, we will have to
take a decision recipient by recipient, donor by donor, in an
individualized fashion, attending to the risk of transmission but
also to the risk of death of the potential candidate. For that
purpose it is completely essential that there is participation of
an infectious disease physician within the transplant team and
communication between donor and recipient hospitals should
be optimized. Lastly, donor-derived disease transmission
should be reported and published using a standardized
deﬁnition system to increase our knowledge [20].
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